Photo taken from Karen D. Wright/LinkedIn
Apr 28, 2024, 11:48
Tovorafenib has now been approved for young patients with relapsed or progressive pediatric low-grade glioma – Dana-Farber Cancer Institute
Dana-Farber Cancer Institute recently shared on LinkedIn:
“For more than a decade, a collaborative team of experts at Dana-Farber, with support from generous families, patient advocates, and the National Cancer Institute (NCI), carried out the scientific detective work that helped transform an orphaned drug into a medicine, tovorafenib, that has now been approved for young patients with relapsed or progressive pediatric low-grade glioma.
‘This is an example of what Dana-Farber is capable of. It’s a really nice example of just how much preclinical work goes into a discovery like this one. An approval for a pediatric tumor doesn’t happen very often. I think this Dana-Farber team can be very proud.’ – Karen D. Wright, MD.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 24, 2024, 00:40
Dec 24, 2024, 00:34
Dec 24, 2024, 00:32
Dec 24, 2024, 00:30
Dec 24, 2024, 00:27
Dec 24, 2024, 00:24
Dec 24, 2024, 00:16
Dec 23, 2024, 21:21
Dec 23, 2024, 21:19